Ozempic vs Mounjaro for Type 2 Diabetes UK: Which Is Better for Blood Sugar?

The headline difference between Ozempic and Mounjaro in Type 2 diabetes trials comes down to glycaemic control. In head-to-head trials, Mounjaro (tirzepatide) reduced HbA1c by approximately 2.4% from baseline, whilst Ozempic (semaglutide) achieved reductions of around 1.5%. Both figures are clinically significant — a 1% reduction in HbA1c is associated with meaningful reductions in microvascular complications — but Mounjaro's dual mechanism consistently produces deeper glycaemic improvements.

These figures come from the SURPASS trial programme (tirzepatide) and the SUSTAIN trials (semaglutide). Importantly, both trials enrolled patients with established Type 2 diabetes who had not achieved adequate control on oral medications alone.

Key HbA1c comparison points: - Mounjaro 15mg reduced HbA1c by a mean of 2.58% in SURPASS-2 - Ozempic 1mg reduced HbA1c by a mean of 1.86% in the same SURPASS-2 trial - A greater proportion of Mounjaro patients achieved HbA1c below 6.5% (near-normal range) - Both medications are superior to most oral diabetes agents including SGLT-2 inhibitors and DPP-4 inhibitors in head-to-head data

For patients with significantly elevated HbA1c (above 9–10%), the additional glucose-lowering power of Mounjaro may be particularly relevant.

*This article is for educational purposes only and does not constitute medical advice. Always discuss diabetes medication decisions with your GP, diabetologist or specialist prescriber.*

Both medications are available on the NHS for Type 2 diabetes, but with different eligibility criteria and prescribing restrictions. Understanding these criteria helps you have a more informed conversation with your GP or diabetes team.

Ozempic (semaglutide) on the NHS: - NICE-approved for adults with Type 2 diabetes as add-on therapy when metformin alone is insufficient - Can be used in combination with metformin, SGLT-2 inhibitors, or insulin - Available in 0.5mg and 1mg doses; 2mg dose also licensed but with specific criteria - Typically initiated by a GP or diabetes specialist nurse in primary care

Mounjaro (tirzepatide) on the NHS for T2D: - NICE approved for Type 2 diabetes via TA924 (2024) - Indicated for adults inadequately controlled on oral agents - Prescribing may be restricted to specialist or shared care arrangements in some NHS trusts during rollout - Access can vary by Integrated Care Board (ICB) — some areas have faster uptake than others

Practical considerations for NHS access: - Supply constraints have affected both medications in recent years; your pharmacy can advise on current availability - NICE recommends stopping treatment if HbA1c reduction is less than 1% after 6 months at the highest tolerated dose - Both medications are injectable — your GP or diabetes nurse should offer injection technique training

If you are not currently eligible under NHS criteria, private prescribing is available through specialist weight management and diabetes clinics.

Understanding why Mounjaro outperforms Ozempic on glycaemia requires a brief look at their mechanisms of action.

Ozempic (semaglutide) is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after eating. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite.

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist — a first-in-class mechanism. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

Why dual agonism adds benefit in T2D: - GIP receptors are expressed in beta cells; GIP stimulates insulin secretion through a complementary pathway to GLP-1 - In people with Type 2 diabetes, the GIP response is often blunted — tirzepatide appears to restore or amplify GIP signalling - The combined GIP+GLP-1 effect produces greater insulin secretion at the same or lower glucose levels - GIP also has effects on glucagon suppression that may complement GLP-1's action

Clinical implication: The dual mechanism explains why Mounjaro consistently produces deeper HbA1c reductions. It is not simply a more potent GLP-1 agonist — it works through an additive pathway that semaglutide alone cannot replicate.

For patients who have failed on GLP-1 therapy (including liraglutide or semaglutide), this distinct mechanism means Mounjaro may still produce meaningful improvements.

For people with Type 2 diabetes, cardiovascular risk management is often as important as glucose control. Both medications have published cardiovascular outcomes data, though the evidence base differs in maturity.

Ozempic — SUSTAIN-6 trial: - Demonstrated non-inferiority and superiority for the primary MACE (major adverse cardiovascular events) endpoint - 26% relative risk reduction in MACE versus placebo in patients with established cardiovascular disease or high CV risk - Subsequent FLOW trial (2024) demonstrated significant renal protection benefits for semaglutide - Ozempic has one of the strongest cardiovascular evidence bases of any diabetes medication

Mounjaro — SURPASS-CVOT (SURMOUNT-MMO): - Dedicated cardiovascular outcomes trial completed in 2024 - Showed significant reductions in MACE in patients with obesity and established cardiovascular disease - Data in T2D-specific cardiovascular outcomes is still maturing compared with semaglutide's longer track record

For patients with established heart disease: - Ozempic has longer cardiovascular safety data and may be preferred by cardiologists for patients with recent MI or stroke - Mounjaro's superior weight loss (which reduces cardiovascular risk) and emerging MACE data are increasingly compelling - Guidelines from the ADA and EASD now recommend GLP-1 agonists or SGLT-2 inhibitors as first injectable choice in T2D patients with established cardiovascular disease

Your diabetes team will weigh cardiovascular history, current medications, and individual risk factors when choosing between these agents.

Cost is a practical consideration for many patients, particularly those accessing treatment privately or managing supply issues.

On the NHS (with valid prescription): - Both medications are available at the standard NHS prescription charge (currently £9.90 per item, 2025/26 rate) for those who pay - Many patients with Type 2 diabetes qualify for free NHS prescriptions under the medical exemption certificate (MedEx) scheme — check your eligibility - Cost to the NHS (not patient cost) differs significantly: Mounjaro is generally more expensive per unit than Ozempic at equivalent doses

Private prescribing costs (approximate 2025/26): - Ozempic: approximately £100–£150 per month for the 0.5mg/1mg doses - Mounjaro: approximately £150–£250 per month depending on dose and supplier - Consultation fees with private prescribers typically add £50–£150 per appointment

Cost-effectiveness for T2D: - NICE assessed Mounjaro as cost-effective for the NHS at the agreed commercial price, based on superior HbA1c reduction and weight loss reducing downstream complications - For privately-paying patients, the superior glycaemic outcomes of Mounjaro may justify the additional cost — discuss this with your prescriber based on your baseline HbA1c

Supply considerations: Both semaglutide and tirzepatide have experienced UK supply shortages. The MHRA and NICE have issued guidance prioritising supply for diabetes patients over weight-loss-only patients when shortages occur. Ensure your prescription is clearly marked with your diabetes diagnosis.

*This article is for educational purposes only and does not constitute medical advice. Medication eligibility and NHS access criteria may change; always verify current guidance with your healthcare team or the NICE website.*